Alnylam Pharmaceuticals
ALNY
$190.83
Share price
0.21%
Change (1 day)
44.45%
Change (1 year)
Categories
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
Alnylam Pharmaceuticals (ALNY) - Net assets
Net assets on the balance sheet as of December 2022 : -$0.16 B
According to Alnylam Pharmaceuticals
's latest financial reports the company has -$0.16 B in net assets.
A company’s net assets is the sum of its assets minus the sum of its liabilities.
Alnylam Pharmaceuticals - Net assets on balance sheet (from 2003 to 2022)
Net assets by year
| Year | Net assets | Change |
|---|---|---|
| 2022-12-31 | $-0.16 B | -126.9% |
| 2021-12-31 | $0.58 B | -42.12% |
| 2020-12-31 | $1.01 B | -29.36% |
| 2019-12-31 | $1.43 B | 10.5% |
| 2018-12-31 | $1.30 B | -26.29% |
| 2017-12-31 | $1.76 B | 91.96% |
| 2016-12-31 | $0.92 B | -27.24% |
| 2015-12-31 | $1.26 B | 35.08% |
| 2014-12-31 | $0.93 B | 246.32% |
| 2013-12-31 | $0.27 B | 101.67% |
| 2012-12-31 | $0.13 B | 13.61% |
| 2011-12-31 | $0.11 B | -25.43% |
| 2010-12-31 | $0.15 B | -11.09% |
| 2009-12-31 | $0.17 B | -11.95% |
| 2008-12-31 | $0.20 B | 1.48% |
| 2007-12-31 | $0.19 B | -1% |
| 2006-12-31 | $0.20 B | 225.63% |
| 2005-12-31 | $61.77 M | 33.89% |
| 2004-12-31 | $46.14 M | -272.77% |
| 2003-12-31 | $-26.71 M | 474.84% |
| 2002-12-31 | $-4.65 M |
Net assets for similar companies or competitors
| Company | Net assets | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | $52.14 B | -33,054.75% | 🇨🇭 Switzerland |
 Sanofi SNY | $80.48 B | -50,968.58% | 🇫🇷 France |
 Regeneron Pharmaceuticals REGN | $22.66 B | -14,424.09% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | $0.71 B | -550.47% | 🇺🇸 USA |
 Regulus Therapeutics RGLS | $33.29 M | -121.04% | 🇺🇸 USA |
 OPKO Health
OPK | $1.55 B | -1,080.77% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | $8.69 B | -5,592.88% | 🇮🇱 Israel |
 Arrowhead Pharmaceuticals
ARWR | $0.46 B | -393.96% | 🇺🇸 USA |